Cellular Dynamics lowers IPO target
This article was originally published in Clinica
Executive Summary
Some more details have emerged about Cellular Dynamics’ initial public offering: the firm now plans to offer 3.846 million shares at $12 each (from a previous range of $12-14), giving a total of $46.2m. It has also granted the underwriters the right to purchase an additional 576,900 shares, which would give it an extra $6.9m – $53.m altogether, a little short of its previous target of $57.5m, based on the $13 per share midpoint (www.clinica.co.uk, 11 July 2013). The company started trading on Nasdaq on 25 July under the ticker symbol ICEL – its share price had dropped 14% to $10.34 by midday. Cellular Dynamics (Madison, Wisconsin) develops stem cell technologies for in vitro drug development, in vivo cellular therapeutics and stem cell banking.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.